Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.53 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.53 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.53 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.53 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28029638 | 0.85 | CLK4 (0.72) | DYRK1ACLK4DYRK1BMAPTCYP1A1 | |
| SCHEMBL15650217 | 0.83 | ADORA2A (0.57) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL27268065 | 0.83 | DYRK1A (0.54) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL14638214 | 0.83 | DYRK1A (0.60) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL29470234 | 0.81 | DYRK1A (0.58) | DYRK1ACLK4MAPTCYP1A1CYP1A2 | |
| SCHEMBL3630297 | 0.81 | DYRK1A (0.58) | DYRK1ACLK4MAPTCYP1A1CYP1A2 | |
| SCHEMBL12775202 | 0.80 | DYRK1A (0.51) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL12775540 | 0.80 | DYRK1A (0.51) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL17561032 | 0.80 | DYRK1A (0.51) | DYRK1ACLK4DYRK1BCYP1A1CYP1A2 | |
| SCHEMBL12844510 | 0.80 | DYRK1A (0.54) | DYRK1ACLK4DYRK1BMAPTCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | DYRK1A 4529/4885CLK4 3880/4885DYRK1B 4434/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | DYRK1A 1361/4885CLK4 3637/4885DYRK1B 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.